Esophageal Cancer News and Research

RSS

Esophageal Cancer is cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach). Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

Study finds long-term use of bone-strengthening drugs increase risk of oesophageal cancer

People who take bone-strengthening pills called bisphosphonates over a long period of time could be more likely to develop cancer of the oesophagus (gullet), new research suggests.

9 Sep 2010

NIH announces award to improve human microbiome research

The National Institutes of Health today announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease.

8 Sep 2010

Cancer Research UK data finds increase in Oesophageal cancer rates among men

Oesophageal cancer rates in men have risen by 50 per cent over the last 25 years, according to new figures published by Cancer Research UK today.In 1983 around 2,600 men were diagnosed with oesophageal cancer - cancer of the food pipe - and according to the latest figures around 5,100 men were diagnosed with the disease.

30 Aug 2010

Eight signs of cancer: Study

Scientists have now identified eight signs of cancer that need immediate attention. These can predict the risk of cancer with such accuracy in certain age groups that patients should be referred to a specialist straight away unless there is a good explanation that is is something else.

30 Aug 2010

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Cascade Technologies, Inc. announced today that its wholly owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule.

27 Aug 2010

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Cascade Technologies, Inc., announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will receive NIH research funding through a collaboration with Omega Optical of Brattleboro, Vermont. This effort will accelerate development of a new class of medical endoscopes enhanced with proprietary multispectral imaging technology. The principal investigators on the project are Dr. Gary Carver, Director of Research at Omega Optical, and Dr. Daniel L. Farkas, Chairman and CEO of SMI.

11 Aug 2010

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

CTI second-quarter total net operating expenses decrease to $20.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the second quarter ended June 30, 2010.

5 Aug 2010

New trend in management of post-liver transplantation biliary strictures

Endoscopic intervention has emerged to become the first line treatment for benign biliary strictures following liver transplantation. The current endoscopic approach involves repetitive dilatation of the stricture and placement of multiple large-diameter parallel plastic stents with frequent stent exchange to prevent biliary infection.

3 Aug 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Recent studies suggest that MSCs possess a greater differentiation potential than once thought and several hepatic differentiation protocols from bone marrow cells have been established. However, the incidence of bone marrow-derived hepatocytes was low. Moreover, a long culture period is needed in most cases.

31 Jul 2010

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Malnutrition is an important factor, influencing both morbidity and recovery after surgery. The early detection of nutritional risk would allow early intervention, which may prevent later complications. A traditional nutritional assessment often includes dietary and medical evaluations to identify significant weight loss over time, significantly low or high body weight(BW), skinfold thickness, serum nutritional factor levels and functional measurements of muscle strength.

31 Jul 2010

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.

31 Jul 2010

CD74 can serve as prognostic marker for colorectal cancer

CD74 is a protein that is expressed in and on cells of the immune system, such as B lymphocytes and antigen presenting cells. This protein is known for its function in facilitating antigen presentation enabling the immune response. Additionally, Professor Shachar's lab has previously shown that CD74 serves as a survival receptor on cells of the immune system, and that its stimulation by its natural ligand -migration inhibitory factor (MIF)- prevents apoptosis (self destruction) of these cells. It was shown that CD74 is markedly expressed on numerous tumors - hematologic as well as epithelial, and can serve as a prognostic marker. CD74's expression and function on colon intestinal epithelial cells is controversial.

31 Jul 2010

Functional MRI can be used to assess tumor viability

Pancreatic ductal adenocarcinoma (the disease commonly referred to as pancreatic cancer) carries the worst prognosis of any cancer. As current treatments offer minimal benefit, entirely new approaches are needed. Given the success of local therapies, as opposed to intravenous systemic therapies, for liver diseases (such as hepatocellular carcinoma), it is thought that similar local therapies may benefit patients with pancreatic cancer. To develop such therapies, it would be useful to devise targets that are easy to obtain and can indicate the efficacy of these new therapies in models of pancreatic cancer.

31 Jul 2010

BARRX Medical closes $15 million Series D financing

BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.

14 Jul 2010

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

People diagnosed with breast, bowel and ovarian cancers and non-Hodgkin's lymphoma are today twice as likely to survive for at least 10 years as those diagnosed in the early 1970s according to new figures1 released by Cancer Research UK.

12 Jul 2010

DGP/tTG Screen assay may be best initial test for suspected celiac disease: Study

Diagnosis of celiac disease is based on a characteristic enteropathy in an intestinal biopsy and evidence that these changes are gluten-triggered. The appropriate use of simpler and more accurate tools would add reliability to the diagnosis of celiac disease. Thus, the celiac disease-related serology might have a key role in defining new diagnostic standards for celiac disease.

9 Jul 2010

Esophageal Cancer News and Research

Further Reading

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Study finds long-term use of bone-strengthening drugs increase risk of oesophageal cancer

NIH announces award to improve human microbiome research

Cancer Research UK data finds increase in Oesophageal cancer rates among men

Eight signs of cancer: Study

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

SMI/Omega development team receives fund to develop prototype fast multispectral endoscope

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

CTI second-quarter total net operating expenses decrease to $20.0 million

New trend in management of post-liver transplantation biliary strictures

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Exposure of mBM-MSCs to VPA increases hepatic differentiation

Patients with malignant gastrointestinal disease show high prevalence of malnutrition

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

CD74 can serve as prognostic marker for colorectal cancer

Functional MRI can be used to assess tumor viability

BARRX Medical closes $15 million Series D financing

Survival rates for people diagnosed with once-deadly cancer increase: Cancer Research UK

DGP/tTG Screen assay may be best initial test for suspected celiac disease: Study

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News